---
title: "Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291355288.md"
description: "Stifel Nicolaus analyst Alex Thompson maintained a Buy rating on Viridian Therapeutics (VRDN) with a $40 price target. This follows a recent Buy from Truist Financial's Gregory Renza, while Wells Fargo previously held a Hold rating. Thompson is recognized as a top 100 analyst with a strong track record in the healthcare sector."
datetime: "2026-07-01T02:05:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291355288.md)
  - [en](https://longbridge.com/en/news/291355288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291355288.md)
generator: "portal-rs"
---

# Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $40.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Thompson CFA is a top 100 analyst with an average return of 47.0% and a 70.50% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Cullinan Management, and Argenx Se.

In addition to Stifel Nicolaus, Viridian Therapeutics also received a Buy from Truist Financial’s Gregory Renza in a report issued yesterday. However, on June 17, Wells Fargo maintained a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

### Related Stocks

- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Repligen CEO, CFO to join Wells Fargo Healthcare Conference analyst discussion](https://longbridge.com/en/news/297037160.md)
- [11,589 Shares in Wells Fargo & Company $WFC Bought by MASTERINVEST Kapitalanlage GmbH](https://longbridge.com/en/news/297399011.md)
- [N.E.W. Advisory Services LLC Makes New $2.46 Million Investment in Wells Fargo & Company $WFC](https://longbridge.com/en/news/296677889.md)
- [Viridian Therapeutics Chief Legal Officer Jennifer Tousignant disposes of common shares worth $348,194](https://longbridge.com/en/news/296547459.md)
- [Royaland adds Nazario Matachione to board of directors](https://longbridge.com/en/news/296926591.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**